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Abstract
Background: Vincristine, a type of vinca alkaloid, is widely used in the treatment of various childhood and adult
malignancies. A well-known side effect of vincristine is its neurotoxicity and it is rarely indicted in vagus nerve
involvement. Vincristine induced vocal cord palsy is a potentially reversible condition, with the mainstay of
therapy being withdrawal of the offending drug. However, there are no clear guidelines regarding the possibility
of re-treatment with the causative agent.
Case presentation: A 58 year old Asian male presented with constipation and abdominal distension. Diagnostic
investigations revealed stage IVB diffuse large B cell lymphoma (DLBCL). The patient was subsequently started on
R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone). On day twelve of receiving
course four of R-CHOP, our patient presented to the hospital with a history of hoarseness of voice. Clinical and
radiological examination revealed bilateral vocal cord palsy. Tracheostomy was done in view of a compromised
airway. The patient subsequently went on to receive two more cycles of R-CHOP. Two weeks later Flexible
laryngoscopy showed no lesion and the vocal cords were moving normally. The tracheostomy was removed. His
voice has improved since and the patient is currently in remission.
Conclusion: The occurrence of vincristine induced vocal cord palsy has been well reported in the literature. We
strongly believe that our patient developed vocal cord palsy secondary to vincristine. The uniqueness of our
patient’s case lies in successful re-treatment of our patient with the offending drug. To the best of our knowledge
this is the third instance where a patient was successfully re-treated with vincristine after having developed vocal
cord palsy as a result of its use.
Keywords: Vincristine, Vocal cord palsy, Re-treatment

Background
Vincristine, a type of vinca alkaloid, is widely used in the
treatment of various childhood and adult malignancies.
Peripheral neuropathy is a well-known and recognized
side effect of this drug. However, there atypical neurotoxic
manifestations of vincristine, some of which may be fatal.
Early recognition of such neurological complications and
their prompt management may lead to complete recovery.
We present a case of a fifty eight year old man receiving R-CHOP for DLBCL who suddenly developed bilateral vocal cord palsy secondary to vincristine induced
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neurotoxicity. He had spontaneous recovery of neurological function despite continuation of the drug.

Case presentation
We report the case of a 58 year old man who presented in
August 2012 with complaints of constipation and abdominal distension. His workup revealed stage IVB diffuse large
B cell lymphoma (DLBCL). He was subsequently started
on systemic chemotherapy with R- CHOP (Rituximab
375 mg/m2, Cyclophosphamide 750 mg/m2, Doxorubicin
50 mg/m2, Vincristine 1.8 mg/m2,, and Prednisolone
50 mg/m2,) with an excellent clinical response. He received
four courses of R-CHOP uneventfully till November 2012.
On day twelve of course four, the patient presented to the
hospital with a history of hoarseness of voice, difficulty in
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breathing and cough. On physical examination the patient
was found to have bilateral wheeze and stridor. The patient
was not taking any antibacterial or antifungal drugs at that
point in time. Laboratory work up was significant for neutropenia with an absolute neutrophil count (ANC) of 336.
CT was performed, which showed a hyper dense mass lesion involving right aryepiglottic fold extending into right
vocal cord, which was new and not present on the earlier
scan (Figure 1). The remainder of the scan revealed significant improvement of overall disease process with substantial reduction in size of enlarged mesenteric lymph nodes
and resolution of gross ascites along with non-visualization
of diffuse omental nodularity, caking and retroperitoneal
lymph nodes.
Fiber-optic laryngoscopy was performed, which showed
swelling in the posterior part of right vocal cord, both
vocal cords fixed with a narrow glottic opening. Tracheostomy was done in view of a compromised airway. Intraoperatively, the right vocal cord appeared inflamed and
was biopsied. Biopsy revealed severe acute and chronic inflammation with no evidence of malignancy.
The patient was discharged from hospital and continued antibiotics outpatient. Subsequently flexible laryngoscopy showed left vocal cord moving normally and
right vocal cord showing limited movement. The patient then received two more courses of R-CHOP till
January 2013, with full dose of vincristine, as the main
differential for vocal cord palsy was mainly infection.
The vocal cords had not regained normal function till
that point in time.
Two weeks after completion of therapy flexible laryngoscopy showed no lesion and the vocal cords were moving normally. The tracheostomy was removed. His voice
has improved since. A positron emission tomogram done
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after six courses of R-CHOP show no residual disease and
to date he remains disease free.

Discussion
Rituximab with CHOP like chemotherapy is the standard
of care in patients with diffuse large B cell lymphoma of
which vincristine is an essential component [1,2]. Vincristine is known to cause various side effects such as constipation, hair loss, hyponatremia however neurotoxicity is
the most common amongst them [3]. Vincristine is postulated to interfere with microtubule formation and cause
axonal degeneration [4]. Factors leading to more severe
neurotoxicity include hypersensitivity to the drug, preexisting liver dysfunction, hereditary neuropathy, and concomitant use of certain drugs, such as allopurinol, erythromycin, isoniazid, mitomycin, phenytoin and itraconazole
[5,6]. Vincristine induced neurotoxicity can present as a
mixed sensorimotor neuropathy, autonomic dysfunction
and less commonly cranial nerve involvement and encephalopathy. The cranial nerve involvement can be
present as transient cortical blindness, hearing loss, facial
palsy, occulomotor nerve dysfunction, jaw pain as a manifestation of trigeminal neuropathy, facial palsy and rarely
recurrent laryngeal nerve palsy which can result in vocal
cord palsy [7,8]. Vocal cord paralysis can be due to peripheral damage to the laryngeal nerve or to the vagus nerve
nuclei and its origin within the central nervous system [9].
Bilateral involvement is usually due to involvement of the
vagal nuclei while unilateral involvement is believed to be
due to peripheral damage of the vagus nerve [10].
Vincristine induced vocal cord palsy has mainly been reported in the pediatrics age group, with few case reports
in adult. Its prevalence is said to about 1.36% in pediatric
patients [11]. From literature review it is evident that

Figure 1 CT scan of the neck showing a hyper dense mass lesion involving right aryepiglottic fold extending into right vocal cord.
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Table 1 Literature review of cases of Vincristine-Induced Laryngeal Paralysis (VLP) in whom full dose of vincristine was
re-administered
Authors

Diagnosis

Age/Sex

Manifestation Airway intervention Duration of paralysis Administration of vincristine

Ahmed et al. [16] Acute lymphoblastic 2 yr/M
leukemia

Bilateral VCP

No

6 months

Redeveloped hoarseness on
receiving full dose. VCR
Ommited

Kuruvilla et al. [11] Rhabdomyosarcoma 3 yr/M
of testicles

Left VCP

No

4 weeks

Gradually received complete dose.

Farrugia [14]

Acute lymphoblastic 18 months/F Bilateral VCP
leukemia

No

4 weeks

Redeveloped hoarseness on
receiving full dose. Dose
reduced to 1/3rd subsequently

Burns et al. [17]

Hodgkin’s disease

No

5 weeks

Received full dose uneventfully.

48 yr/M

Left VCP

vincristine induced neuropathy is related to dose intensity along with cumulative dose effect [7]. In most patients, vincristine induced vocal cord palsy occurs beyond
its second dose.
There is no specific treatment of vincristine induced
vocal cord palsy. Pyridoxine and pyridostigmine has been
associated with an early recovery (within 1–2 weeks) of
vincristine induced peripheral neuropathy in a case series
of patients [12]. The role of glutamic acid in decreasing
vincristine induced neurotoxicity has been analyzed in
some studies involving rat model [13], however this was
not found to be effective when used in a patient with vincristine induced vocal cord palsy [14]. Overall about 5566% of all pediatrics patients presenting with bilateral
vocal cord paralysis require airway protection with a
tracheostomy [8]. In a case series of 10 pediatrics patients
with vincristine induced bilateral vocal cord palsy, only 2
required tracheostomy [11]. Vincristine induced vocal
cord palsy may be reversible and complete recovery occurs in 6–9 months [6,7,15].
Besides our patient, there are only four other reported
cases of reintroduction of vincristine at full dose [11,14,
16,17] and in two of them there was a relapse [11,14,16]
(Table 1). The reason for continuing vincristine at full
dose in our case was that at that point our differential for
vocal cord palsy was mainly infection, and the mass at the
right aryepiglottic fold was a red herring. In retrospect, it
was thought that the mass effect was likely a result of the
paralyzed, fixed vocal cord causing distortion of the aryepiglottic fold. The patient had a tracheostomy for airway
protection and chemotherapy was continued with vincristine at full dose. Interestingly, our patient regained vocal
cord function despite continuation of vincristine and was
successfully decanulated two weeks after completion of
chemotherapy.

Conclusion
In conclusion, we report a case of vincristine induced bilateral recurrent laryngeal nerve palsy who had full recovery of vocal cord palsy within two weeks after completion
of definitive treatment of diffuse large B cell lymphoma.

We think that vincristine induced vocal cord palsy is potentially reversible and careful protection of airway is
needed when completion of treatment is the goal.
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